We will use cookies and other information to optimize your experience. By continuing to browse, you consent to our use. For details, please read Privacy Policy
Gongwin Biopharm Co., Ltd.
Language
  • 繁體中文
  • English
  • About Us
    • Company Profile
    • Company presentation
    • History
    • Our Team
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • News&Media
    • Press Release
    • Latest Updates
    • Events
  • Pipeline
  • Products
    • Product Features
      • DM
    • PTS302 NSCLC-SMAO
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS100 HCC
      • Medical column
      • Treatment Result or Case
      • Clinical Trials
      • Pipeline development milestones
    • PTS-02 ACC
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS500 MPE
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • Anti-tumor drug for canine use
      • DM
      • Introduction
      • Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
      • History of Animal Clinical Trials
      • Case Acceptance Indications
      • Superficial malignant tumor in canine
      • Malignant melanoma of the canine
      • Lipoma of the canine and feline
      • Malignant bladder tumor of the canine and feline
      • Video
  • R & D
    • Core Technology
    • Mechanism of Action
    • R & D Center
    • Published Paper
  • Investors
    • Financial information
      • Company annual report
      • Financial report
      • Monthly revenue
      • Legal person briefing
    • Corporate Governance
      • Corporate governance structure
      • Board of Directors
      • Committee
      • Internal audit
      • Company regulations
      • Other corporate governance information
    • Shareholder area
      • Shareholders' meeting
      • Dividend distribution
      • Material message
      • Stock price message
      • Investor Relations Contact Window
      • Stock agency
    • Interest relationship
      • Interested parties communicate with the company
  • Youtube
  • Contact
  1. Home
  2. Products
DOMINOInterior Design
Products
  • Product Features
    • DM
  • PTS302 NSCLC-SMAO
    • Medical column
    • Treatment Result or Case
    • Pipeline development milestones
  • PTS100 HCC
    • Medical column
    • Treatment Result or Case
    • Clinical Trials
    • Pipeline development milestones
  • PTS-02 ACC
    • Medical column
    • Treatment Result or Case
    • Pipeline development milestones
  • PTS500 MPE
    • Medical column
    • Treatment Result or Case
    • Pipeline development milestones
  • Anti-tumor drug for canine use
    • DM
    • Introduction
    • Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
    • History of Animal Clinical Trials
    • Case Acceptance Indications
    • Superficial malignant tumor in canine
    • Malignant melanoma of the canine
    • Lipoma of the canine and feline
    • Malignant bladder tumor of the canine and feline
    • Video
DM
DM
Detail
DM

Back
CONTACTS
  • Gongwin Biopharm Holdings Co., Ltd.
  • 02-2503-5282
  • E-mail info@gongwinbiopharm.com
  • Address 3F., No.80, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City 104, Taiwan (R.O.C.)
NAVIGATION
  • About Us
  • News&Media
  • Pipeline
  • Progress
  • Products
  • R & D
  • Investors
  • Join Us
  • Youtube
  • Video
  • Facebook
  • Contact
  • Terms
  • Disclaimer
Facebook fan page

Copyright © 2018 Gongwinbiopharm All rights reserved. Web Design | DMO

  • 繁體中文
  • English
Language
  • 繁體中文
  • English
  • About Us
    • Company Profile
    • Company presentation
    • History
    • Our Team
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • News&Media
    • Press Release
    • Latest Updates
    • Events
  • Pipeline
  • Products
    • Product Features
      • DM
    • PTS302 NSCLC-SMAO
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS100 HCC
      • Medical column
      • Treatment Result or Case
      • Clinical Trials
      • Pipeline development milestones
    • PTS-02 ACC
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • PTS500 MPE
      • Medical column
      • Treatment Result or Case
      • Pipeline development milestones
    • Anti-tumor drug for canine use
      • DM
      • Introduction
      • Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
      • History of Animal Clinical Trials
      • Case Acceptance Indications
      • Superficial malignant tumor in canine
      • Malignant melanoma of the canine
      • Lipoma of the canine and feline
      • Malignant bladder tumor of the canine and feline
      • Video
  • R & D
    • Core Technology
    • Mechanism of Action
    • R & D Center
    • Published Paper
  • Investors
    • Financial information
      • Company annual report
      • Financial report
      • Monthly revenue
      • Legal person briefing
    • Corporate Governance
      • Corporate governance structure
      • Board of Directors
      • Committee
      • Internal audit
      • Company regulations
      • Other corporate governance information
    • Shareholder area
      • Shareholders' meeting
      • Dividend distribution
      • Material message
      • Stock price message
      • Investor Relations Contact Window
      • Stock agency
    • Interest relationship
      • Interested parties communicate with the company
  • Youtube
  • Contact